Amrendar Kumar, Abhilasha Singh, Swati Agarwal, Ramkishan Agarwal
Amity Institute of Biotechnology, Amity University, Lucknow, India


The specificity of drug targets is a great challenge in the pharma-proteomics field of virology. To eradicate such hurdle, here we have taken a novel step to study the relation between drugs and corresponding drug target network using the advanced concepts of proteomics and network pharmacology. Usually the process of drug discovery is a very time consuming multi-step process against a series of various in vivo biological screens. Here we present a study on antiviral herbal lead compounds and their potential binding affinity to the various effectors and supporter molecules of HIV Type 1 and HIV Type 2. There are 3 phases of HIV infection, acute, latency and AIDS. Acute infection lasts for several weeks and may include some common symptoms but latent stage can last for more than 20 years and doesn’t show any symptoms. During the latent stage the HIV gets hide into the human host cells. This makes the HIV very harder to diagnose even passing the host through many common clinical tests. During the infection HIV converts its RNA genome into DNA and then import the DNA to host’s cell nucleus. In nucleus the HIV DNA integrate with the genome of host with the help of HIV Integerase. In this case if a drug is used to attack the HIV, it will also damage the host. The literature mining gives the details of various proteins and their strains which either causes the HIV or supports the virus inside the host to their activity. These are further subjected to design a well connected regulatory network of HIV. The resultant network is then extrapolated to proteomics and pharmacological level to sort out the highest interacting protein. The network is statistically analyzed and represented by the graphical interpretation to encounter the hub nodes and their locally parsed neighbors, ligand verses multi receptor docking and the propensity of drug targets in hub nodes and related sub networks. Read more…

Please follow and like us:
News Reporter